It is very uncertain whether other pharmaceutical agents changes risk of secondary hemorrhage; cycloplegics compared with placebo or other control interventions (very low certainty).
Other pharmaceutical agents showed no clear difference in risk of secondary hemorrhage; aspirin compared with placebo or other control interventions (low certainty).
Non‐pharmaceutical interventions showed no clear difference in short‐term visual acuity between 20/20 and 20/60 at end of… compared with control (low certainty).
Non‐pharmaceutical interventions showed no clear difference in final visual acuity between 20/20 and 20/50; monocular vs binocular… compared with control (low certainty).
Non‐pharmaceutical interventions showed no clear difference in risk of secondary hemorrhage; monocular vs binocular eye patching compared with control (low certainty).
Non‐pharmaceutical interventions showed no clear difference in risk of secondary hemorrhage; ambulatory treatment vs bed rest compared with control (low certainty).
Systemic aminocaproic acid showed no clear difference in final visual acuity 20/40 or better at resolution of hyphema compared with placebo (low certainty).
Systemic aminocaproic acid may leads to lower secondary hemorrhage at any time point compared with placebo (low certainty).
Systemic aminocaproic acid probably leads to higher adverse effects: nausea or vomiting compared with placebo (moderate certainty).
Topical aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
The review found no eligible studies for this question.
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
Infliximab 5 mg/kg may leads to higher clinical response at week 26 compared with purine analogues (low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 10 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction in CDAI by 70 points at week 4 compared with infliximab 10 mg/kg (very low certainty).
The review found no eligible studies for this question.